LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 238

Search options

  1. Article ; Online: Comparison of the QIAGEN artus HCV QS-RGQ test with the Roche COBAS Ampliprep/COBAS TaqMan HCV test v2.0 for the quantification of HCV-RNA in plasma samples.

    Schønning, Kristian

    Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology

    2014  Volume 60, Issue 4, Page(s) 323–327

    Abstract: Background: Quantification of Hepatitis C Virus (HCV)-RNA is important for the clinical management of patients undergoing antiviral therapy.: Objectives: To compare the quantification of clinical plasma samples by the Roche COBAS AmpliPrep/COBAS ... ...

    Abstract Background: Quantification of Hepatitis C Virus (HCV)-RNA is important for the clinical management of patients undergoing antiviral therapy.
    Objectives: To compare the quantification of clinical plasma samples by the Roche COBAS AmpliPrep/COBAS TaqMan HCV test v2.0 and the artus HCV QS-RGQ test.
    Study design: HCV-RNA viral load in 155 plasma samples from HCV-seropositive individuals was determined using the COBAS test and retrospectively with the artus. Furthermore, a dilution series of an Acrometrix standard was tested with both tests in replicates of five to assess differences in limit of detection and precision.
    Results: Two clinical samples showed inhibition using the artus test and were excluded from analysis. Of the clinical samples, 20 tested negative in both tests, 7 tested positive in the COBAS test and negative in the artus test, and 126 samples were quantified by both tests. The mean overall difference between tests (artus-COBAS) was 0.27 log IU/mL. The mean difference of quantification varied little across genotype 1a, 1b, 2b and 3a (range: +0.15 to +0.35 log IU/mL). Both tests were precise (%CV at 1000 IU/mL 1.1 and 1.8 for the COBAS and artus test, respectively).
    Conclusions: The limit of detection appeared lower in the COBAS test than the artus test when analyzed from a limited number of replicates. Both tests were precise with the artus test quantifying higher than the COBAS test on average. It is therefore recommended to monitor individual patients with the same test throughout treatment.
    MeSH term(s) Antiviral Agents/therapeutic use ; Genotype ; Hepacivirus/genetics ; Hepatitis C, Chronic/blood ; Hepatitis C, Chronic/diagnosis ; Hepatitis C, Chronic/drug therapy ; Humans ; Limit of Detection ; Molecular Diagnostic Techniques ; RNA, Viral/blood ; Reagent Kits, Diagnostic ; Retrospective Studies ; Viral Load/methods
    Chemical Substances Antiviral Agents ; RNA, Viral ; Reagent Kits, Diagnostic
    Language English
    Publishing date 2014-08
    Publishing country Netherlands
    Document type Comparative Study ; Journal Article
    ZDB-ID 1446080-4
    ISSN 1873-5967 ; 1386-6532
    ISSN (online) 1873-5967
    ISSN 1386-6532
    DOI 10.1016/j.jcv.2014.05.002
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Emergence of linezolid-resistant

    Misiakou, Maria-Anna / Hertz, Frederik Boetius / Schønning, Kristian / Häussler, Susanne / Nielsen, Karen Leth

    Microbial genomics

    2023  Volume 9, Issue 7

    Abstract: Linezolid is used as first-line treatment of infections caused by vancomycin- ... ...

    Abstract Linezolid is used as first-line treatment of infections caused by vancomycin-resistant
    MeSH term(s) Humans ; Linezolid/pharmacology ; Anti-Bacterial Agents/pharmacology ; Anti-Bacterial Agents/therapeutic use ; Enterococcus faecium/genetics ; Vancomycin/pharmacology ; Vancomycin/therapeutic use ; Tertiary Care Centers ; Multilocus Sequence Typing ; Vancomycin-Resistant Enterococci/genetics
    Chemical Substances Linezolid (ISQ9I6J12J) ; Anti-Bacterial Agents ; Vancomycin (6Q205EH1VU)
    Language English
    Publishing date 2023-07-06
    Publishing country England
    Document type Journal Article
    ZDB-ID 2835258-0
    ISSN 2057-5858 ; 2057-5858
    ISSN (online) 2057-5858
    ISSN 2057-5858
    DOI 10.1099/mgen.0.001055
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Evaluation of the Hologic Panther Fusion MRSA Assay for the detection of MRSA in ESwab specimens obtained from nose, throat, and perineum.

    Bartels, Mette Damkjær / Knudsen, Danah / Westh, Henrik / Schønning, Kristian

    European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology

    2021  Volume 40, Issue 10, Page(s) 2177–2183

    Abstract: Enrichment culture (EC) remains gold standard for detecting MRSA colonisation, but molecular methods shorten turnaround time. The CE-marked automated Hologic Panther Fusion MRSA Assay (HPFM) is validated for nasal swabs. We compared HPFM with EC ... ...

    Abstract Enrichment culture (EC) remains gold standard for detecting MRSA colonisation, but molecular methods shorten turnaround time. The CE-marked automated Hologic Panther Fusion MRSA Assay (HPFM) is validated for nasal swabs. We compared HPFM with EC following an in-house PCR for detection of MRSA in nasal, pharyngeal, and perineal ESwabs. The same ESwabs were analysed using HPFM and inoculated in selective Tryptic Soy Broth (TSB) for overnight incubation. TSBs were screened by a PCR targeting nuc, femA, mecA, and mecC. Only samples with PCR results compatible with MRSA presence were inoculated onto 5% blood agar and chromogenic MRSA plates. HPFM detected MRSA in 103 of 132 EC positive samples indicating a sensitivity of 78.0% across sample types. When paired TSBs of 29 EC positive/HPFM negative samples were re-analysed by HPFM, MRSA was detected in 17/29 TSBs indicating that enrichment will increase the sensitivity of HPFM. HPFM analyses of cultured isolates from the remaining 12 EC positive/HPFM negative samples failed to detect orfX. HPFM reported the presence of MRSA in 22 samples where EC failed to identify MRSA. Fifteen of these ESwabs had been kept and direct culture without enrichment identified MRSA in seven samples. HPFM was useful for all sample sites. Compared to EC, the sensitivity of HPFM was limited because of lack of analytical sensitivity and failure to detect all MRSA variants. Failure of some MRSA-containing samples to enrich in cefoxitin-containing TSB indicates an unappreciated limitation of EC, which may lead to underestimation of the specificity of molecular assays.
    MeSH term(s) Humans ; Methicillin-Resistant Staphylococcus aureus/classification ; Methicillin-Resistant Staphylococcus aureus/genetics ; Methicillin-Resistant Staphylococcus aureus/growth & development ; Methicillin-Resistant Staphylococcus aureus/isolation & purification ; Multiplex Polymerase Chain Reaction ; Nose/microbiology ; Perineum/microbiology ; Pharynx/microbiology ; Staphylococcal Infections/diagnosis ; Staphylococcal Infections/microbiology
    Language English
    Publishing date 2021-05-11
    Publishing country Germany
    Document type Evaluation Study ; Journal Article
    ZDB-ID 603155-9
    ISSN 1435-4373 ; 0934-9723 ; 0722-2211
    ISSN (online) 1435-4373
    ISSN 0934-9723 ; 0722-2211
    DOI 10.1007/s10096-021-04272-9
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Performance of PCR-based syndromic testing compared to bacterial culture in patients with suspected pneumonia applying microscopy for quality assessment.

    Andrews, Vigith / Pinholt, Mette / Schneider, Uffe Vest / Schønning, Kristian / Søes, Lillian Marie / Lisby, Gorm

    APMIS : acta pathologica, microbiologica, et immunologica Scandinavica

    2022  Volume 130, Issue 7, Page(s) 417–426

    Abstract: Syndromic testing for lower respiratory tract infections with BioFire® FilmArray® Pneumonia Panel Plus (BF) detects 27 pathogens with a turn-around-time of one hour. We compared the performance of BF with culture. Samples from 298 hospitalized patients ... ...

    Abstract Syndromic testing for lower respiratory tract infections with BioFire® FilmArray® Pneumonia Panel Plus (BF) detects 27 pathogens with a turn-around-time of one hour. We compared the performance of BF with culture. Samples from 298 hospitalized patients with suspected pneumonia routinely sent for culture were also analyzed using BF. Retrospectively, patients were clinically categorized as having "pneumonia" or "no pneumonia." BF and culture were compared by analytical performance, which was evaluated by pathogen concordance, and by clinical performance by comparing pathogen detections in patients with and without pneumonia. The BF results for viruses and atypical bacteria were not included in the performance analysis. In 298 patient samples, BF and culture detected 285 and 142 potential pathogens, respectively. Positive percent agreement (PPA) was 88% (125/142). In patients with community-acquired pneumonia (CAP), clinical sensitivity was 70% and 51%, and specificity was 43% and 71% for BF and culture, respectively. In patients with hospital-acquired pneumonia, the corresponding numbers were 55% and 23%, and 47% and 68%. There was no significant improvement of performance, when only high-quality sputum samples were considered. Efficacy of both BF and culture was low. Both tests are best used in CAP patients for whom the diagnosis has already been clinically established. Indiscriminate use may be clinically misleading and a cause of improper use of antibiotics.
    MeSH term(s) Community-Acquired Infections/diagnosis ; Humans ; Microscopy ; Molecular Diagnostic Techniques/methods ; Multiplex Polymerase Chain Reaction/methods ; Pneumonia/diagnosis ; Polymerase Chain Reaction ; Retrospective Studies
    Language English
    Publishing date 2022-05-22
    Publishing country Denmark
    Document type Journal Article
    ZDB-ID 93340-5
    ISSN 1600-0463 ; 0903-4641
    ISSN (online) 1600-0463
    ISSN 0903-4641
    DOI 10.1111/apm.13232
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Pre-existing, treatment-specific resistance-associated substitutions in hepatitis C virus genotype 1 and 3 and viral RNA titers during treatment with direct-acting antivirals.

    Sølund, Christina / Pedersen, Martin S / Fahnøe, Ulrik / Filskov, Jonathan / Jenssen, Håvard / Weis, Nina / Schønning, Kristian / Bukh, Jens

    APMIS : acta pathologica, microbiologica, et immunologica Scandinavica

    2023  Volume 131, Issue 8, Page(s) 426–433

    Abstract: The introduction of direct-acting antiviral (DAA) treatment of hepatitis C virus (HCV) infected patients has greatly increased treatment success rates. However, viral response kinetics to DAA treatment may depend on pre-existing resistance-associated ... ...

    Abstract The introduction of direct-acting antiviral (DAA) treatment of hepatitis C virus (HCV) infected patients has greatly increased treatment success rates. However, viral response kinetics to DAA treatment may depend on pre-existing resistance-associated substitutions (RASs) in HCV. The aim of this study was to describe how pre-existing RASs affect DAA treatment-induced reduction in HCV RNA titers in HCV genotypes 1- and 3-infected individuals. Patients with HCV genotype 1 infection (N = 31) treated with either sofosbuvir/ledipasvir/ribavirin or paritaprevir/ombitasvir/ritonavir/dasabuvir/ribavirin and HCV genotype 3-infected patients (N = 16) treated with either sofosbuvir/daclatasvir/ribavirin or sofosbuvir/ribavirin were analyzed. HCV RNA levels were determined at baseline and frequently during treatment, and RAS profiles were obtained by deep sequencing at baseline. In total, 33/47 (70.2%) of the patients had baseline RASs. However, treatment-specific RASs were detected at baseline only in 12.9% and 18.8% of HCV genotypes 1- and 3-infected patients, respectively. In genotype 1-infected individuals, reduction in HCV RNA titer during the first week of treatment was not affected by evidence of either treatment-specific RASs or cirrhosis or treatment regimen. In genotype 3-infected individuals receiving sofosbuvir/daclatasvir/ribavirin, the presence of daclatasvir-specific NS5A RASs at baseline correlated with a reduced decline of HCV RNA in the first treatment week. For both genotypes 1- and 3-infected individuals, cirrhosis but not treatment-specific RAS were associated with the time of clearance of HCV RNA. It is, however, important to note that this study involves DAA regimens that were used only during the original introduction of interferon-free DAA-based treatments.
    MeSH term(s) Humans ; Antiviral Agents/therapeutic use ; Sofosbuvir/therapeutic use ; Hepacivirus/genetics ; Ribavirin/therapeutic use ; RNA, Viral/genetics ; Hepatitis C, Chronic/drug therapy ; Drug Therapy, Combination ; Sustained Virologic Response ; Genotype ; Hepatitis C/drug therapy
    Chemical Substances Antiviral Agents ; Sofosbuvir (WJ6CA3ZU8B) ; daclatasvir (LI2427F9CI) ; Ribavirin (49717AWG6K) ; RNA, Viral
    Language English
    Publishing date 2023-06-25
    Publishing country Denmark
    Document type Journal Article
    ZDB-ID 93340-5
    ISSN 1600-0463 ; 0903-4641
    ISSN (online) 1600-0463
    ISSN 0903-4641
    DOI 10.1111/apm.13335
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Identification of a CTX-M-255 β-lactamase containing a G239S substitution selectively conferring resistance to penicillin/β-lactamase inhibitor combinations.

    Andreasen, Minna Rud / Rick, Tim / Alexandersen, Nicolai Riff / Hansen, Katrine Hartung / Pedersen, Martin Schou / Warweitzky, Jakob K / Botelho, Carolina Mastella / Häussler, Susanne / Jelsbak, Lotte / Schønning, Kristian

    The Journal of antimicrobial chemotherapy

    2024  Volume 79, Issue 4, Page(s) 810–814

    Abstract: Objectives: An Escherichia coli isolate, WGS1363, showed resistance to piperacillin/tazobactam but susceptibility to cephalosporins and contained a previously unrecognized β-lactamase, CTX-M-255, as the only acquired β-lactamase. CTX-M-255 was identical ...

    Abstract Objectives: An Escherichia coli isolate, WGS1363, showed resistance to piperacillin/tazobactam but susceptibility to cephalosporins and contained a previously unrecognized β-lactamase, CTX-M-255, as the only acquired β-lactamase. CTX-M-255 was identical to CTX-M-27 except for a G239S substitution. Here, we characterize the hydrolytic spectrum of CTX-M-255 and a previously reported β-lactamase, CTX-M-178, also containing a G239S substitution and compare it to their respective parental enzymes, CTX-M-27 and CTX-M-15.
    Methods: All β-lactamase genes were expressed in E. coli TOP10 and MICs to representative β-lactam-antibiotics were determined. Furthermore, blaCTX-M-15,  blaCTX-M-27, blaCTX-M-178 and blaCTX-M-255 with C-terminal His-tag fusions were affinity purified for enzyme kinetic assays determining Michaelis-Menten kinetic parameters against representative β-lactam-antibiotics and IC50s of clavulanate, sulbactam, tazobactam and avibactam.
    Results: TOP10-transformants expressing blaCTX-M-178 and blaCTX-M-255 showed resistance to penicillin/β-lactamase combinations and susceptibility to cephalothin and cefotaxime in contrast to transformants expressing blaCTX-M-15 and blaCTX-M-27. Determination of enzyme kinetic parameters showed that CTX-M-178 and CTX-M-255 both lacked hydrolytic activity against cephalosporins and showed impaired hydrolytic efficiency against penicillin antibiotics compared to their parental enzymes. Both enzymes appeared more active against piperacillin compared to benzylpenicillin and ampicillin. Compared to their parental enzymes, IC50s of β-lactamase-inhibitors were increased more than 1000-fold for CTX-M-178 and CTX-M-255.
    Conclusions: CTX-M-178 and CTX-M-255, both containing a G239S substitution, conferred resistance to piperacillin/tazobactam and may be characterized as inhibitor-resistant CTX-M β-lactamases. Inhibitor resistance was accompanied by loss of activity against cephalosporins and monobactams. These findings add to the necessary knowledge base for predicting antibiotic susceptibility from genotypic data.
    MeSH term(s) beta-Lactamase Inhibitors/pharmacology ; Anti-Bacterial Agents/pharmacology ; Escherichia coli ; beta-Lactamases/genetics ; Penicillins/pharmacology ; Cephalosporins/pharmacology ; Tazobactam/pharmacology ; Piperacillin/pharmacology ; Monobactams ; Piperacillin, Tazobactam Drug Combination ; Microbial Sensitivity Tests
    Chemical Substances beta-Lactamase Inhibitors ; Anti-Bacterial Agents ; beta-Lactamases (EC 3.5.2.6) ; Penicillins ; Cephalosporins ; Tazobactam (SE10G96M8W) ; Piperacillin (X00B0D5O0E) ; Monobactams ; Piperacillin, Tazobactam Drug Combination (157044-21-8)
    Language English
    Publishing date 2024-02-15
    Publishing country England
    Document type Journal Article
    ZDB-ID 191709-2
    ISSN 1460-2091 ; 0305-7453
    ISSN (online) 1460-2091
    ISSN 0305-7453
    DOI 10.1093/jac/dkae033
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: [Feber efter rejse til Iran].

    Goldschmidt, Maria Ingeborg / Andrews, Vigith / Pedersen, Michael / Schønning, Kristian

    Ugeskrift for laeger

    2020  Volume 182, Issue 23

    Language Danish
    Publishing date 2020-06-08
    Publishing country Denmark
    Document type Journal Article
    ZDB-ID 124102-3
    ISSN 1603-6824 ; 0041-5782
    ISSN (online) 1603-6824
    ISSN 0041-5782
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Within-patient horizontal transfer of pOXA-48 from a hypervirulent

    Nielsen, Karen Leth / Sørensen, Marc / Hertz, Frederik Boëtius / Misiakou, Maria Anna / Hasman, Henrik / Häussler, Susanne / Helleberg, Marie / Schønning, Kristian

    Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin

    2022  Volume 28, Issue 17

    Abstract: ... A ... ...

    Abstract A hypervirulent
    MeSH term(s) Humans ; Klebsiella pneumoniae/genetics ; Serratia marcescens/genetics ; beta-Lactamases/genetics ; Bacterial Proteins/genetics ; Anti-Bacterial Agents/pharmacology ; Anti-Bacterial Agents/therapeutic use ; Klebsiella Infections/drug therapy ; Klebsiella Infections/epidemiology ; Plasmids/genetics ; Denmark/epidemiology
    Chemical Substances beta-Lactamases (EC 3.5.2.6) ; Bacterial Proteins ; Anti-Bacterial Agents
    Language English
    Publishing date 2022-04-13
    Publishing country Sweden
    Document type Journal Article
    ZDB-ID 1338803-4
    ISSN 1560-7917 ; 1025-496X
    ISSN (online) 1560-7917
    ISSN 1025-496X
    DOI 10.2807/1560-7917.ES.2023.28.17.2300196
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Efficacy of piperacillin-tazobactam and cefotaxime against Escherichia coli hyperproducing TEM-1 in a mouse peritonitis infection model.

    Hertz, Frederik Boëtius / Andreasen, Minna Rud / Almind, Stine Radmer / Nielsen, Karen Leth / Hansen, Katrine Hartung / Jelsbak, Lotte / Frimodt-Møller, Niels / Schønning, Kristian

    International journal of antimicrobial agents

    2022  Volume 59, Issue 4, Page(s) 106543

    Abstract: Objectives: Piperacillin-tazobactam (TZP) is a frequently prescribed antibiotic in hospital settings. Reports suggest in vivo efficacy of TZP, despite in vitro resistance of isolates susceptible to cephalosporins. Escherichia coli (E. coli) isolates ... ...

    Abstract Objectives: Piperacillin-tazobactam (TZP) is a frequently prescribed antibiotic in hospital settings. Reports suggest in vivo efficacy of TZP, despite in vitro resistance of isolates susceptible to cephalosporins. Escherichia coli (E. coli) isolates hyperproducing TEM-1 β-lactamase possess this phenotype. This study investigated the influence of tazobactam (TAZ) concentration on piperacillin (PIP) inhibition of such isolates and compared the in vivo efficacy of TZP with cefotaxime (CTX) in an infection model.
    Methods: The PIP MICs for E. coli isolates, either hyperproducing TEM-1 because of promoter substitutions (n = 4) or because of gene amplification (n = 2) or producing an inhibitor-resistant TEM-35 (IRT) (n = 1), were determined using increasing concentrations of TAZ in a checkerboard setup. Furthermore, the efficacy of TZP and CTX against the isolates was investigated in a mouse peritonitis model using antibiotic exposures mimicking human conditions. Isolates producing either OXA-48 or CTX-M-15 β-lactamases were included as controls.
    Results: Using TAZ concentrations ≤ 64 mg/L, one isolate hyperproducing TEM-1 had a PIP MIC of 8 at TAZ 16 mg/L and two additional isolates at TAZ 64 mg/L. In the mouse peritonitis infection model, reduction of bacterial load in the peritoneum was larger for TZP than CTX only for the CTX-M-15-producing isolate. Larger reductions in bacterial load were observed after CTX treatment than TZP treatment for seven of the eight remaining test isolates.
    Conclusions: Piperacillin-tazobactam treatment of E. coli isolates hyperproducing TEM-1 was less effective than CTX treatment and may, for some isolates, be comparable with TZP treatment of isolates producing established resistance markers as IRT or OXA-48.
    MeSH term(s) Animals ; Anti-Bacterial Agents/pharmacology ; Anti-Bacterial Agents/therapeutic use ; Antigens, CD/metabolism ; Cefotaxime/pharmacology ; Cefotaxime/therapeutic use ; Escherichia coli ; Escherichia coli Infections/drug therapy ; Escherichia coli Infections/microbiology ; Mice ; Microbial Sensitivity Tests ; Neoplasm Proteins/metabolism ; Peritonitis ; Piperacillin/pharmacology ; Piperacillin/therapeutic use ; Piperacillin, Tazobactam Drug Combination/pharmacology ; Tazobactam/pharmacology ; Tazobactam/therapeutic use ; beta-Lactamases/genetics
    Chemical Substances Anti-Bacterial Agents ; Antigens, CD ; Neoplasm Proteins ; tumor endothelial marker 1, mouse ; Piperacillin, Tazobactam Drug Combination (157044-21-8) ; beta-Lactamases (EC 3.5.2.6) ; Cefotaxime (N2GI8B1GK7) ; Tazobactam (SE10G96M8W) ; Piperacillin (X00B0D5O0E)
    Language English
    Publishing date 2022-02-06
    Publishing country Netherlands
    Document type Journal Article
    ZDB-ID 1093977-5
    ISSN 1872-7913 ; 0924-8579
    ISSN (online) 1872-7913
    ISSN 0924-8579
    DOI 10.1016/j.ijantimicag.2022.106543
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Comparison of morbidity and mortality after bloodstream infection with vancomycin-resistant versus -susceptible

    Bager, Peter / Kähler, Jonas / Andersson, Mikael / Holzknecht, Barbara Juliane / Kjær Hansen, Sanne Grønvall / Schønning, Kristian / Nielsen, Karen Leth / Koch, Kristoffer / Pinholt, Mette / Voldstedlund, Marianne / Larsen, Anders Rhod / Kristensen, Brian / Mølbak, Kåre / Sönksen, Ute Wolff / Skovgaard, Sissel / Skov, Robert / Hammerum, Anette M

    Emerging microbes & infections

    2024  Volume 13, Issue 1, Page(s) 2309969

    Abstract: The emergence of bloodstream infections (BSI) caused by vancomycin-resistant Enterococci (VRE) has caused concern. Nonetheless, it remains unclear whether these types are associated with an excess risk of severe outcomes when compared with infections ... ...

    Abstract The emergence of bloodstream infections (BSI) caused by vancomycin-resistant Enterococci (VRE) has caused concern. Nonetheless, it remains unclear whether these types are associated with an excess risk of severe outcomes when compared with infections caused by vancomycin-susceptible Enterococci (VSE). This cohort study included hospitalized patients in Denmark with
    MeSH term(s) Humans ; Enterococcus faecium ; Vancomycin ; Cohort Studies ; Gram-Positive Bacterial Infections/drug therapy ; Gram-Positive Bacterial Infections/epidemiology ; Enterococcus ; Sepsis ; Morbidity ; Denmark/epidemiology
    Chemical Substances Vancomycin (6Q205EH1VU)
    Language English
    Publishing date 2024-03-11
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2681359-2
    ISSN 2222-1751 ; 2222-1751
    ISSN (online) 2222-1751
    ISSN 2222-1751
    DOI 10.1080/22221751.2024.2309969
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top